📣 VC round data is live. Check it out!

Aier EYE Hospital Group Valuation Multiples

Discover Aier EYE Hospital Group's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Apollo Hospitals, DaVita, Tenet Healthcare, Rede D'Or São Luiz and more.

Aier EYE Hospital Group Overview

About Aier EYE Hospital Group

Aier Eye Hospital Group Co Ltd provides international ophthalmic technology and management services in China. The company offers services in myopia surgery, cataract surgery, pediatric eye plastic surgery, myopia prevention, and control to patients. The group also enables high-standard medical care.


Founded

2003

HQ

China

Employees

42.7K

Financials (LTM)

Revenue: $3B
EBITDA: $997M

EV

$13B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Aier EYE Hospital Group Financials

Aier EYE Hospital Group reported last 12-month revenue of $3B and EBITDA of $997M.

In the same LTM period, Aier EYE Hospital Group generated $2B in gross profit, $997M in EBITDA, and $513M in net income.

Revenue (LTM)


Aier EYE Hospital Group P&L

In the most recent fiscal year, Aier EYE Hospital Group reported revenue of $3B and EBITDA of $960M.

Aier EYE Hospital Group is profitable as of last fiscal year, with gross margin of 47%, EBITDA margin of 29%, and net margin of 14%.

See analyst estimates for Aier EYE Hospital Group
LTMLast FY202320242025202620272028
Revenue$3B$3B$3B$3B$3B
Gross Profit$2B$2B$2B$1B$2B
Gross Margin48%47%51%48%47%
EBITDA$997M$960M$901M$952M$957M
EBITDA Margin29%29%30%31%29%
EBIT Margin21%22%27%23%22%
Net Profit$513M$479M$496M$526M$479M
Net Margin15%14%16%17%14%

Financial data powered by Morningstar, Inc.

Aier EYE Hospital Group Stock Performance

Aier EYE Hospital Group has current market cap of $13B, and enterprise value of $13B.

Market Cap Evolution


Aier EYE Hospital Group's stock price is $1.36.

Aier EYE Hospital Group share price increased by 1.1% in the last 30 days, and decreased by 25.0% in the last year.

Aier EYE Hospital Group has an EPS (earnings per share) of $0.05.

See more trading valuation data for Aier EYE Hospital Group
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$13B$13B1.1%1.1%-2.5%-25.0%$0.05

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Aier EYE Hospital Group Valuation Multiples

Aier EYE Hospital Group trades at 3.7x EV/Revenue multiple, and 12.8x EV/EBITDA.

See NTM and 2027E valuation multiples for Aier EYE Hospital Group

EV / Revenue (LTM)


Aier EYE Hospital Group Financial Valuation Multiples

As of June 2, 2026, Aier EYE Hospital Group has market cap of $13B and EV of $13B.

Aier EYE Hospital Group has a P/E ratio of 24.7x.

LTMLast FY202320242025202620272028
EV/Revenue3.7x3.9x4.3x4.1x3.9x
EV/EBITDA12.8x13.3x14.2x13.4x13.4x
EV/EBIT17.5x17.7x15.6x18.1x17.7x
EV/Gross Profit7.9x8.2x8.4x8.6x8.2x
P/E24.7x26.5x25.5x24.1x26.5x
EV/FCF23.3x22.3x19.6x28.4x22.3x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Aier EYE Hospital Group Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Aier EYE Hospital Group Margins & Growth Rates

Aier EYE Hospital Group grew revenue by 9% and EBITDA by 9% in the last fiscal year.

In the most recent fiscal year, Aier EYE Hospital Group reported gross margin of 47%, EBITDA margin of 29%, and net margin of 14%.

See estimated margins and future growth rates for Aier EYE Hospital Group

Aier EYE Hospital Group Margins

Last FY202420252026202720282029
Gross Margin47%48%47%48%
EBITDA Margin29%31%29%29%
EBIT Margin22%23%22%22%
Net Margin14%17%14%16%
FCF Margin17%15%17%16%

Aier EYE Hospital Group Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth9%3%7%9%
Gross Profit Growth11%(2%)4%11%
EBITDA Growth9%6%0%10%
EBIT Growth9%(14%)2%9%
Net Profit Growth18%6%(9%)18%
FCF Growth(2%)(31%)27%(2%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Aier EYE Hospital Group Operational KPIs

Aier EYE Hospital Group's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.

Aier EYE Hospital Group's Rule of 40 is 38% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Aier EYE Hospital Group's Rule of X is 53% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Aier EYE Hospital Group
LTMLast FY202320242025202620272028
Rule of 4039%38%---
Bessemer Rule of X55%53%---
Revenue per Employee-$0.1M---
Opex per Employee-$0.0M---
S&M Expenses to Revenue10%10%6%6%5%
G&A Expenses to Revenue14%14%4%4%4%
R&D Expenses to Revenue1%1%2%2%1%
Opex to Revenue-25%24%25%25%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Aier EYE Hospital Group Competitors

Aier EYE Hospital Group competitors include Apollo Hospitals, DaVita, Tenet Healthcare, Rede D'Or São Luiz, Encompass Health, Max Healthcare Institute, Mayapada Hospital, Bangkok Dusit Medical Services, Universal Health Services and Fortis Healthcare.

Most Aier EYE Hospital Group public comparables operate across Hospitals & Clinics.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Apollo Hospitals4.9x4.8x30.8x31.9x
DaVita1.8x1.8x8.8x8.7x
Tenet Healthcare1.2x1.2x5.5x5.4x
Rede D'Or São Luiz1.5x1.5x7.1x8.1x
Encompass Health2.2x2.1x9.2x9.8x
Max Healthcare Institute11.2x10.4x36.9x35.5x
Mayapada Hospital66.9x-696.3x-
Bangkok Dusit Medical Services2.5x2.5x10.5x10.5x

This data is available for Pro users. Sign up to see all Aier EYE Hospital Group competitors and their valuation data.

Start Free Trial

Aier EYE Hospital Group VC Funding History

Before going public, Aier EYE Hospital Group raised $2M in total equity funding, across 2 rounds.


Aier EYE Hospital Group Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
May-17Series AShanghai Jinao Investment Management; Taiyuan Shixian Yiliao Industry Development Enterprise$2M--
Dec-16AngelLinfen Jianning Eye Hospital$400K--

Acquisitions by Aier EYE Hospital Group

Aier EYE Hospital Group has acquired 1 company to date.

Last acquisition by Aier EYE Hospital Group was on April 12th 2017. Aier EYE Hospital Group acquired Clinica Baviera for $189M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Aier EYE Hospital Group

Clinica Baviera
Description
Clinica Baviera SA operates ophthalmological clinics. It is involved in the diagnosis, treatment, and monitoring of various types of ophthalmological disorders. It offers diagnosis and treatment for various eye problems such as long-sightedness, short-sightedness, astigmatism, cataracts and eye strain.
HQ CountrySpain
HQ City
Madrid
Deal Date12 Apr 2017
Valuation$189M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Aier EYE Hospital Group acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by Aier EYE Hospital Group

Aier EYE Hospital Group has invested in 6 companies to date.

Latest investment by Aier EYE Hospital Group was on September 5th 2024. Aier EYE Hospital Group invested in Sieran Medical in their $14M Seed round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Aier EYE Hospital Group

Sieran Medical
Svision
SIYO Bio-Tech
Zhaoke Ophthalmology
Description
Sieran Medical is a medical device company delivering minimally invasive surgical solutions for ophthalmology. Based in Shanghai, China, it develops precision instruments for cataract, glaucoma, and retinal procedures, incorporating intelligent imaging and robotic assistance for improved accuracy.
Svision is a Suzhou-based healthcare startup manufacturing high-end ophthalmic imaging devices such as optical coherence tomography systems for diagnosing retinal diseases.
SIYO Bio-Tech is a Chinese manufacturing enterprise specializing in synthetic biology for microbial enzymes and small molecules from extreme environments. The firm's products support gene detection, in vitro diagnostics, cosmetics, pharmaceuticals, food production, and animal nutrition via siyobio.com.
Zhaoke Ophthalmology Ltd is an ophthalmic pharmaceutical company dedicated to the research, development, manufacture and commercialization of therapies that address unmet medical needs. The company has three flagship drug assets progressing towards potential market approval: NVK002 for myopia, CsA Ophthalmic Gel for DED and TAB014 for wAMD; and two drug assets in the clinical stage BRIMOCHOL PF for presbyopia and ZKY001 for corneal epithelial defects. Geographically the company operates in Hong Kong, Mainland China, South Korea, and Others.
HQ CountryChinaChinaChinaChina
HQ City
Suzhou
Luoyang
Beijing
-
Deal Date5 Sep 20249 Mar 202323 Feb 202212 Oct 2020
RoundSeedSeries CSeries BSeries B
Raised$14M$44M$32M$145M
InvestorsAibo Qingshi Venture Capital Fund; Aier EYE Hospital Group; Apricot Capital; Highlight Capital; Insight Capital; Jiale CapitalAddor Capital; Aier EYE Hospital Group; CD Capital; China Life Private Equity Investment; CICC; Flyfot Ventures; Lang Sheng Investment; Ming capital; Qianhai Fund of Funds; Shenzhen Capital GroupAier EYE Hospital Group; CICC; Sinvo GroupAier EYE Hospital Group; Coyote Ventures; Hillhouse Investment; Loyal Valley Capital; OrbiMed; Panacea Venture; TPG
Valuationundisclosed$348Mundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Aier EYE Hospital Group investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Aier EYE Hospital Group

When was Aier EYE Hospital Group founded?Aier EYE Hospital Group was founded in 2003.
Where is Aier EYE Hospital Group headquartered?Aier EYE Hospital Group is headquartered in China.
How many employees does Aier EYE Hospital Group have?As of today, Aier EYE Hospital Group has over 42K employees.
Who is the CEO of Aier EYE Hospital Group?Aier EYE Hospital Group's CEO is Zhong Han.
Is Aier EYE Hospital Group publicly listed?Yes, Aier EYE Hospital Group is a public company listed on Shenzhen Stock Exchange.
What is the stock symbol of Aier EYE Hospital Group?Aier EYE Hospital Group trades under 300015 ticker.
When did Aier EYE Hospital Group go public?Aier EYE Hospital Group went public in 2009.
Who are competitors of Aier EYE Hospital Group?Aier EYE Hospital Group main competitors include Apollo Hospitals, DaVita, Tenet Healthcare, Rede D'Or São Luiz, Encompass Health, Max Healthcare Institute, Mayapada Hospital, Bangkok Dusit Medical Services, Universal Health Services, Fortis Healthcare.
What is the current market cap of Aier EYE Hospital Group?Aier EYE Hospital Group's current market cap is $13B.
What is the current revenue of Aier EYE Hospital Group?Aier EYE Hospital Group's last 12 months revenue is $3B.
What is the current revenue growth of Aier EYE Hospital Group?Aier EYE Hospital Group revenue growth (NTM/LTM) is 10%.
What is the current EV/Revenue multiple of Aier EYE Hospital Group?Current revenue multiple of Aier EYE Hospital Group is 3.7x.
What is the current EBITDA of Aier EYE Hospital Group?Aier EYE Hospital Group's last 12 months EBITDA is $997M.
What is Aier EYE Hospital Group's EBITDA margin?Aier EYE Hospital Group's last 12 months EBITDA margin is 29%.
What is the current EV/EBITDA multiple of Aier EYE Hospital Group?Current EBITDA multiple of Aier EYE Hospital Group is 12.8x.
What is the current FCF of Aier EYE Hospital Group?Aier EYE Hospital Group's last 12 months FCF is $550M.
What is Aier EYE Hospital Group's FCF margin?Aier EYE Hospital Group's last 12 months FCF margin is 16%.
What is the current EV/FCF multiple of Aier EYE Hospital Group?Current FCF multiple of Aier EYE Hospital Group is 23.3x.
How many companies Aier EYE Hospital Group has acquired to date?As of June 2026, Aier EYE Hospital Group has acquired 1 company.
What was the largest acquisition by Aier EYE Hospital Group?$189M acquisition of Clinica Baviera on 12th April 2017 was the largest M&A Aier EYE Hospital Group has done to date.
What companies Aier EYE Hospital Group acquired?Aier EYE Hospital Group acquired Clinica Baviera.
In how many companies Aier EYE Hospital Group has invested to date?As of June 2026, Aier EYE Hospital Group has invested in 6 companies.
What was the last Aier EYE Hospital Group investment?On 5th September 2024 Aier EYE Hospital Group invested in Sieran Medical, participating in a $14M Seed round, alongside Aibo Qingshi Venture Capital Fund, Apricot Capital, Highlight Capital, Insight Capital, and Jiale Capital.

See public comps similar to Aier EYE Hospital Group

Lists including Aier EYE Hospital Group

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial